ZHONG JI LS (00767) subsidiary Zhongli Hainan plans to jointly establish the "International Oncology Precision Medicine Center" with Hainan Boao.

ZHONG JI LS (00767) announced that on September 13, 2025, its indirect non-wholly owned subsidiary Zhongli (Hainan) Life Science Technology Co., Ltd. (Zhongli Hainan) signed a cooperation agreement with Hainan Boao Super Hospital Limited (Hainan Boao). Zhongli Hainan and Hainan Boao jointly established the "International Oncology Precision Medicine Center" (Medical Center). Hainan Boao is responsible for providing the site for the center and providing services on the "1+X" platform, including but not limited to outpatient, inpatient, examination, treatment, surgery, etc. Zhongli Hainan is responsible for the operation of the center and providing expertise, specialized technology, and equipment support. Both parties will engage in diagnosis and treatment activities for patients and various research projects. The Board of Directors believes that the outlook for the health and longevity science market is broad, as affluent customers worldwide are more willing to accept and spend on longevity science applications to enhance their overall health and immunity, and promote the rejuvenation of their bodies. The signing of the cooperation agreement aligns with the Group's business development strategy and plan in the health and longevity science sector, and will benefit the Group's future business development by laying a solid foundation for further expanding in the domestic market. The Board of Directors believes that signing the cooperation agreement will further enhance the Group's layout in the field of longevity science diagnosis and medical services, and open up new sources of income in the longevity science field for the Group, aiming to bring more stable and sustainable income growth in the long run.